CNN —The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder. About 18% of American adults – more than 1 in 6 – say they are depressed or receiving treatment for depression, a 2023 Gallup report found. Rejoyn is designed to serve as an adjunct to antidepressants for these partial responders, according to the news release. They were assigned to use either the Rejoyn app or a sham app that gave memory tasks that did not involve cognitive-emotional training or cognitive behavioral therapy. There is also the question of how engaged patients will be with the app, Torous said.

---

Persons: Rejoyn, Dr, John Kraus, Otsuka, Brian Iacoviello, John Torous, Torous, ”, ” Otsuka, Sanjay Gupta, “, ” Torous Organizations: CNN, Food and Drug Administration, Otsuka Pharmaceutical, Therapeutics, Gallup, Research, Click Therapeutics, Digital Psychiatry, Beth Israel Deaconess Medical, FDA, ” Otsuka Pharmaceutical, CNN Health